These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 18615074)
41. SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis. Felix RS; Colleoni GW; Caballero OL; Yamamoto M; Almeida MS; Andrade VC; Chauffaille Mde L; Silva WA; Begnami MD; Soares FA; Simpson AJ; Zago MA; Vettore AL Cancer Lett; 2009 Jun; 278(1):41-8. PubMed ID: 19171422 [TBL] [Abstract][Full Text] [Related]
42. Cyclosporine A inhibits colorectal cancer proliferation probably by regulating expression levels of c-Myc, p21(WAF1/CIP1) and proliferating cell nuclear antigen. Masuo T; Okamura S; Zhang Y; Mori M Cancer Lett; 2009 Nov; 285(1):66-72. PubMed ID: 19481339 [TBL] [Abstract][Full Text] [Related]
43. Loss of histidine decarboxylase as a marker of malignant transformation and dedifferentiation of B-cells infiltrating the skin. A case report of a therapy-resistant multiple myeloma complicated by skin infiltration. Varkonyi J; Karádi I; Szocs K; Sugár I; Sápi Z; Marschalko M; Pállinger E; Darvas Z; Falus A Acta Oncol; 2008; 47(3):458-61. PubMed ID: 17851872 [No Abstract] [Full Text] [Related]
44. A new MAFia in cancer. Eychène A; Rocques N; Pouponnot C Nat Rev Cancer; 2008 Sep; 8(9):683-93. PubMed ID: 19143053 [TBL] [Abstract][Full Text] [Related]
49. Hierarchy of mono- and biallelic Munawar U; Rasche L; Müller N; Vogt C; Da-Via M; Haertle L; Arampatzi P; Dietrich S; Roth M; Garitano-Trojaola A; Steinhardt MJ; Strifler S; Gallardo M; Martinez-Lopez J; Bargou RC; Heckel T; Einsele H; Stühmer T; Kortüm KM; Barrio S Blood; 2019 Sep; 134(10):836-840. PubMed ID: 31340981 [No Abstract] [Full Text] [Related]
50. C-Myc transrepression and cell transformation. Lee LA; Dang CV Curr Top Microbiol Immunol; 1997; 224():131-5. PubMed ID: 9308236 [No Abstract] [Full Text] [Related]
51. Biologic and clinical significance of cytokine production in B-cell malignancies. Torcia M; Aldinucci D; Carossino AM; Imreh F; Cozzolino F Eur J Haematol Suppl; 1989; 51():35-42. PubMed ID: 2697593 [TBL] [Abstract][Full Text] [Related]
52. Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker. Ryu D; Kim HJ; Joung JG; Lee HO; Bae JS; Kim SJ; Kim H; Park WY; Kim K Oncotarget; 2016 Jul; 7(30):47127-47133. PubMed ID: 27223072 [TBL] [Abstract][Full Text] [Related]
53. Oncogene addiction. Weinstein IB; Joe A Cancer Res; 2008 May; 68(9):3077-80; discussion 3080. PubMed ID: 18451130 [TBL] [Abstract][Full Text] [Related]
54. Cancer. Taking a back door to target Myc. Evan G Science; 2012 Jan; 335(6066):293-4. PubMed ID: 22267799 [No Abstract] [Full Text] [Related]
55. [Cellular origin of multiple myeloma]. Qi J; Hao Y Zhonghua Xue Ye Xue Za Zhi; 1999 May; 20(5):275-7. PubMed ID: 11601218 [No Abstract] [Full Text] [Related]
56. MYC dysregulation in the progression of multiple myeloma. Misund K; Keane N; Stein CK; Asmann YW; Day G; Welsh S; Van Wier SA; Riggs DL; Ahmann G; Chesi M; Viswanatha DS; Kumar SK; Dispenzieri A; Gonzalez-Calle V; Kyle RA; O'Dwyer M; Rajkumar SV; Kortüm KM; Keats JJ; ; Fonseca R; Stewart AK; Kuehl WM; Braggio E; Bergsagel PL Leukemia; 2020 Jan; 34(1):322-326. PubMed ID: 31439946 [No Abstract] [Full Text] [Related]
57. The role of c-myc during normal B cell proliferation, and as B cells undergo malignant transformation. Snow EC Curr Top Microbiol Immunol; 1997; 224():211-20. PubMed ID: 9308244 [No Abstract] [Full Text] [Related]